ArticleBMC rheumatology2026
Psychometric validation of the Bulgarian Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire: linking quality of life with disease activity in axial spondyloarthritis.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAssessing quality of life in patients with axial spondyloarthritis (axSpA) is essential for capturing the full burden of the disease beyond clinical and imaging findings. Quality of life measures support clinicians in identifying unmet patient needs and informing treatment decisions. The aim of this study was to develop and validate the first Bulgarian version of the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire.
methodsThe development of the Bulgarian version of the ASQoL followed a three-stage process: translation, field testing, and psychometric evaluation. Following translation and field testing of the ASQoL, the psychometric evaluation involved administering the ASQoL to a random sample of axSpA patients on two occasions, 10–20 days apart, to assess its reliability and validity. Reliability was examined using internal consistency (Cronbach’s alpha) and test–retest reliability (Spearman’s rank correlation). Convergent validity was evaluated using the Short Form Health Survey Version 2 (SF-36v2) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP). Known-groups validity was assessed based on self-perceived general health and self-perceived disease activity.
resultsThe Bulgarian version of the ASQoL demonstrated high internal consistency, with Cronbach’s alpha coefficients of 0.884 at time 1 and 0.882 at time 2. Test-retest reliability was excellent (Spearman’s ρ = 0.98, p < 0.001), indicating strong temporal stability. Convergent validity was supported by moderate correlations between ASQoL scores and relevant SF-36 domains, with the strongest associations observed for Physical Functioning, General Health, and Role Limitations. ASQoL scores showed a strong positive correlation with ASDAS-CRP (Spearman’s ρ = 0.70, p < 0.001), indicating close alignment between patient-reported quality of life and clinical disease activity. Known-groups validity was demonstrated by the ASQoL’s ability to distinguish between patient subgroups based on self-perceived general health and self-perceived disease activity, with statistically significant differences in ASQoL scores across general health categories.
conclusionsThe Bulgarian ASQoL demonstrated strong psychometric properties, confirming its reliability and validity in accurately capturing the impact of axSpA on patients’ quality of life.
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.